Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 190

1.

PAI-1 -675 4G/5G polymorphism in association with diabetes and diabetic complications susceptibility: a meta-analysis study.

Xu K, Liu X, Yang F, Cui D, Shi Y, Shen C, Tang W, Yang T.

PLoS One. 2013 Nov 5;8(11):e79150. doi: 10.1371/journal.pone.0079150. eCollection 2013.

2.

Plasminogen activator inhibitor-1 4G/5G polymorphism and retinopathy risk in type 2 diabetes: a meta-analysis.

Zhang T, Pang C, Li N, Zhou E, Zhao K.

BMC Med. 2013 Jan 2;11:1. doi: 10.1186/1741-7015-11-1.

3.

Association between PAI-1 4G/5G polymorphism and diabetic nephropathy: a meta-analysis in the Chinese population.

Gao WF, Guo YB, Bai Y, Ding XY, Yan YJ, Wu ZQ.

Int Urol Nephrol. 2016 Sep;48(9):1483-9. doi: 10.1007/s11255-016-1333-9. Epub 2016 Jun 6. Review.

PMID:
27272255
4.
5.
6.

PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus.

Funk M, Endler G, Exner M, Marculescu R, Endler L, Abrahamian H, Mauler H, Grimm A, Raith M, Mannhalter C, Prager R, Irsigler K, Wagner OF.

Wien Klin Wochenschr. 2005 Oct;117(19-20):707-10.

PMID:
16416371
7.

Diabetic retinopathy, PAI-1 4G/5G and -844G/A polymorphisms, and changes in circulating PAI-1 levels in Tunisian type 2 diabetes patients.

Ezzidi I, Mtiraoui N, Chaieb M, Kacem M, Mahjoub T, Almawi WY.

Diabetes Metab. 2009 Jun;35(3):214-9. doi: 10.1016/j.diabet.2008.12.002. Epub 2009 May 5.

PMID:
19419896
8.

Diabetic retinopathy, promoter (4G/5G) polymorphism of PAI-1 gene, and PAI-1 activity in Pima Indians with type 2 diabetes.

Nagi DK, McCormack LJ, Mohamed-Ali V, Yudkin JS, Knowler WC, Grant PJ.

Diabetes Care. 1997 Aug;20(8):1304-9.

PMID:
9250459
9.

Allelic frequency of the PAI-1 4G/5G promoter polymorphism in patients with type 2 diabetes mellitus and lack of association with PAI-1 plasma levels.

Zietz B, Buechler C, Drobnik W, Herfarth H, Schölmerich J, Schäffler A.

Endocr Res. 2004 Aug;30(3):443-53.

PMID:
15554360
10.

Association of plasminogen activator inhibitor-1 gene polymorphism and type 2 diabetic nephropathy.

Xu F, Liu H, Sun Y.

Ren Fail. 2016;38(1):157-62. doi: 10.3109/0886022X.2015.1089464. Epub 2015 Nov 29.

PMID:
26616527
11.

Plasminogen activator inhibitor-1 4G/5G polymorphism and ischemic stroke risk: a meta-analysis in Chinese population.

Cao Y, Chen W, Qian Y, Zeng Y, Liu W.

Int J Neurosci. 2014 Dec;124(12):874-81. doi: 10.3109/00207454.2014.886577. Epub 2014 Feb 21.

PMID:
24472072
12.

Plasminogen activator inhibitor-1 4G/5G and the MTHFR 677C/T polymorphisms and susceptibility to polycystic ovary syndrome: a meta-analysis.

Lee YH, Song GG.

Eur J Obstet Gynecol Reprod Biol. 2014 Apr;175:8-14. doi: 10.1016/j.ejogrb.2013.12.030. Epub 2014 Jan 3. Review.

PMID:
24439532
13.

Association between the SERPINE1 (PAI-1) 4G/5G insertion/deletion promoter polymorphism (rs1799889) and pre-eclampsia: a systematic review and meta-analysis.

Zhao L, Bracken MB, Dewan AT, Chen S.

Mol Hum Reprod. 2013 Mar;19(3):136-43. doi: 10.1093/molehr/gas056. Epub 2012 Nov 23. Review.

PMID:
23180602
14.
15.

Association between the plasminogen activator inhibitor-1 4G/5G polymorphism and risk of venous thromboembolism: a meta-analysis.

Wang J, Wang C, Chen N, Shu C, Guo X, He Y, Zhou Y.

Thromb Res. 2014 Dec;134(6):1241-8. doi: 10.1016/j.thromres.2014.09.035. Epub 2014 Oct 5.

PMID:
25450536
16.

The -675 4G/5G polymorphism in plasminogen activator inhibitor-1 gene is associated with risk of asthma: a meta-analysis.

Nie W, Li B, Xiu QY.

PLoS One. 2012;7(3):e34385. doi: 10.1371/journal.pone.0034385. Epub 2012 Mar 27.

17.

Association of tissue plasminogen activator and plasminogen activator inhibitor polymorphism with myocardial infarction: a meta-analysis.

Gong LL, Peng JH, Han FF, Zhu J, Fang LH, Wang YH, Du GH, Wang HY, Liu LH.

Thromb Res. 2012 Sep;130(3):e43-51. doi: 10.1016/j.thromres.2012.06.015. Epub 2012 Jul 6.

PMID:
22771216
18.

Clinicopathological significance of plasminogen activator inhibitor-1 promoter 4G/5G polymorphism in breast cancer: a meta-analysis.

Lee JH, Kim Y, Choi JW, Kim YS.

Arch Med Res. 2013 Jan;44(1):39-45. doi: 10.1016/j.arcmed.2012.12.002. Epub 2013 Jan 3.

PMID:
23291383
19.

PAI-1 4G/5G polymorphism contributes to cancer susceptibility: evidence from meta-analysis.

Wang S, Cao Q, Wang X, Li B, Tang M, Yuan W, Fang J, Qian J, Qin C, Zhang W.

PLoS One. 2013;8(2):e56797. doi: 10.1371/journal.pone.0056797. Epub 2013 Feb 20.

20.

Plasminogen activator inhibitor type-1 (PAI-1) polymorphism 4G/5G is associated with prostate cancer among men with a positive family history.

Jorgenson E, Deitcher SR, Cicek M, Liu X, Plummer S, Casey G, Witte JS.

Prostate. 2007 Feb 1;67(2):172-7.

PMID:
17044080

Supplemental Content

Support Center